Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer

    NEXT STORY
    Global Vaccines Industry Report 2020: Market Projected to Cross $81 Billion by 2027 – Increase in the Adoption of Combination Vaccines in Prevention Strategies by the Government
    PREV STORY
    CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cue Biopharma Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, CUE-101, in Treatment of HPV-driven Cancers

    author_avatar
    NASDAQ Market News

    Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association

    Newark, NJ, June 14, 2018 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug ...

    author_avatar
    NASDAQ Market News

    Rexahn Reports First Quarter 2018 Financial Results

    ROCKVILLE, Md., May 07, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a ...

    author_avatar
    NASDAQ Market News